Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: Results of an expanded access programme in Poland

Wspolczesna Onkologia

Volumn 16, Issue 2, 2012, Pages 170-175

  Kowalski, Dariusz M ^a   Krzakowski, Maciej ^a   Ramlau, Rodryg ^b   Jaskiewicz, Piotr ^a   Janowicz Zebrowska, Anna ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b Department of Oncology   (Poland)

Author keywords

Erlotinib; Non small cell lung cancer; Prognostic factors; TRUST

Indexed keywords

ERLOTINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CLINICAL ASSESSMENT; CONJUNCTIVITIS; CONTROLLED STUDY; CYTOLOGY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEALTH PROGRAM; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 4 CLINICAL TRIAL; POLAND; PROGNOSIS; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84861735872     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2012.28798     Document Type: Article

References (35)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30. (Pubitemid 40310185)
2. Rachtan J, Sokołowski A, Niepsuj S, Zemła B, Zwierko M. Familial lung cancer risk among women in Poland. Lung Cancer 2009; 65: 138-43.
3. Chemotherapy in non-small cell lung cancer: ameta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899-909.
4. Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003; 123: 226S-43S. (Pubitemid 36135720)
5. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2007; 2: 845-53. (Pubitemid 47361027)
6. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single agent or a 2-agent chemotherapy regimen in advanced non-small cell lung cancer: a meta-analysis. JAMA 2004; 292: 470-84. (Pubitemid 38988956)
7. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 3852-9. (Pubitemid 41079865)
8. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99: 847-57.
9. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: a Eastern Cooperative Oncology Group Study. J Clin Oncol 1986; 4: 702-9. (Pubitemid 16114717)
10. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-103. (Pubitemid 30324363)
11. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97. (Pubitemid 41079796)
12. Krzakowski M. Leczenie drugiej linii w niedrobnokomórkowym raku płuca. Onkol Prakt Klin 2009; 5: 1-8.
13. Takeda K, Negoro S, Tamura T, et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 2009; 20: 835-41.
14. Krzakowski M, Douillard JY, Ramlau R, et al. Phase III study of vinflunine versus docetaxel in patients with advanced non-small cell lung cancer previously treated with a platinium containing regimen. J Clin Oncol 2007; 25 (Suppl. 18): 387.
15. Ramlau R, Gervais R, Krzakowski M, et al. Phase III study comparing topotecan to intravenous docetaxel in patients with pretreated advanced non-small cell lung cancer. J Clin Oncol 2006; 24: 2800-7. (Pubitemid 46630579)
16. Ciardiello F, De Vita F, Orditura M, Tortora G. The role of EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol 2004; 16: 130-5. (Pubitemid 38402525)
17. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123-32. (Pubitemid 41058344)
18. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-44. (Pubitemid 41058345)
19. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-84. (Pubitemid 41103588)
20. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-94. (Pubitemid 41103589)
21. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545-52. (Pubitemid 46733081)
22. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin in advanced non-small cell lung cancer. J Clin Oncol 2005; 23: 5892-9.
23. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (the IDEAL Trial). J Clin Oncol 2003; 21: 2237-46. (Pubitemid 46621858)
24. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58. (Pubitemid 37432975)
25. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Evaluation in Lung Cancer). Lancet 2005; 366: 1527-37. (Pubitemid 41540110)
26. Niho S, Ichionese Y, Tamura T, et al. Results of a randomized phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small cell lung cancer who failed one or two chemotherapy regimens. J Clin Oncol 2007 ASCO Annual Meeting Proceedings, Part I. Vol. 25, No. 18S: LBA 7509.
27. Douillard JY, Kim ES, Hirsh V, et al. Phase III, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small cell lung cancer who have previously received platinum-based chemotherapy (INTREST). Eur J Cancer Supplements 2007; 6: 2.
28. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trial Group Study BR.21. J Clin Oncol 2006; 24: 3831-7. (Pubitemid 46630729)
29. Ardizzoni A, Evangelia R, Mikhail L, et al. Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007; 2 (Suppl. 4): S342.
30. Groen H, Arrieta OG, Riska H, et al. The global TRUST study of erlotinib in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26: 1900.
31. Tiseo M, Gridelli C, Cascinu S, et al. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data from Italy. Lung Cancer 2009; 64: 199-206.
32. Clark GM, Zborowski DM, Culbertson JL, et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol 2006; 1: 837-46. (Pubitemid 47181390)
33. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500. (Pubitemid 38720929)
34. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal factor receptor antagonists in non-small cell lung cancer. J Clin Oncol 2007; 25: 587-95. (Pubitemid 350002967)
35. Gridelli C, Ardizzoni A, Ciardiello F, et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 2008; 3: 430-40. (Pubitemid 351489488)